Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech: A Buy For Growth Potential
01:40am, Sunday, 06'th Nov 2022
Children suffering dystrophic epidermolysis bullosa (DEB), a serious genetic disease, are affectionately called butterfly children, depicting their fragile, recurrent blistering skin with chronic open
Krystal Biotech to Present at Chardan's 6th Annual Genetic Medicines Conference
07:00am, Thursday, 29'th Sep 2022
PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Thursday, 08'th Sep 2022
PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the
Krystal Biotech: Solid Performance, Let's Keep Holding
09:20am, Thursday, 18'th Aug 2022
Krystal Bio (KRYS) has performed well in the last two months that I have had it. Its B-VEC looks highly approvable.
Can This Healthcare Stock Keep Beating the Market?
07:50am, Saturday, 30'th Jul 2022
This biotech looks promising, but there are potential pitfalls to consider.
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
07:00am, Wednesday, 06'th Jul 2022
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the W
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
11:00am, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Ap
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
07:00am, Tuesday, 07'th Jun 2022
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the G
Krystal Biotech: High Potential, Buy-At-Dips Stock
11:36am, Wednesday, 25'th May 2022
In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter.
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
11:30pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 s
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Monday, 09'th May 2022 Zacks Investment Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
08:15pm, Monday, 09'th May 2022 GlobeNewswire Inc.
PITTSBURGH, May 09, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational pro
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
07:00am, Tuesday, 03'rd May 2022
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chi
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
03:00pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
PITTSBURGH, March 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that results from the
